Patient characteristics
. | . | . | . | . | . | No. of cells infused, × 107/kg . | . | . | Chimerism status . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age at CBT . | Sex . | Diagnosis . | No. of HLA mismatches . | TBI . | . | Pre-CBT patient HCMV serology . | aGVHD (grade) . | 3-5 mo after CBT . | 12-15 mo after CBT . | |
| CBT-sib | |||||||||||
| 1 | 8 y | F | Thal | NA | No | 2.7 | Positive | Yes (II) | CC | CC | |
| 2 | 5 y | M | Thal | NA | No | 4 | Positive | No | CC | CC | |
| 3 | 3 y | F | NBL | NA | No | 14 | Positive | No | CC | CC | |
| 4 | 7 y | M | Thal | NA | No | 2.1 | Positive | No | MC | MC | |
| 5 | 10 y | F | FA | NA | No | 1.4 | Positive | No | CC | CC | |
| 6 | 4 y | M | Thal | NA | No | 6 | Positive | No | MC | MC | |
| 7 | 6 y | F | Thal | NA | No | 2.5 | Positive | No | MC | MC | |
| 8 | 13 y | F | Thal | NA | No | 4 | Positive | No | MC | MC | |
| 9 | 19 y | F | Thal | NA | No | 2.6 | Positive | No | MC | MC | |
| 10 | 10 y | M | DC | NA | No | 2.2 | Positive | No | MC | MC | |
| 11 | 4 y | F | ALL | NA | Yes | 3.2 | Negative | No | CC | CC | |
| CBT-ud | |||||||||||
| 12 | 5 y | M | ALL | 1 class II | Yes | 9.7 | Positive | Yes (II) | CC | CC | |
| 13 | 5 mo | F | Osteop | 0 | No | 13 | Negative | Yes (II) | CC | CC | |
| 14 | 5 y | M | ALL | 0 | Yes | 4 | Positive | Yes (I) | CC | CC | |
| 15 | 5 y | M | ALL | 1 class I | Yes | 4.7 | Negative | No | CC | CC | |
| 16 | 2 y | M | JMML | 1 class I | No | 5.2 | Positive | Yes (II) | CC | CC | |
. | . | . | . | . | . | No. of cells infused, × 107/kg . | . | . | Chimerism status . | . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age at CBT . | Sex . | Diagnosis . | No. of HLA mismatches . | TBI . | . | Pre-CBT patient HCMV serology . | aGVHD (grade) . | 3-5 mo after CBT . | 12-15 mo after CBT . | |
| CBT-sib | |||||||||||
| 1 | 8 y | F | Thal | NA | No | 2.7 | Positive | Yes (II) | CC | CC | |
| 2 | 5 y | M | Thal | NA | No | 4 | Positive | No | CC | CC | |
| 3 | 3 y | F | NBL | NA | No | 14 | Positive | No | CC | CC | |
| 4 | 7 y | M | Thal | NA | No | 2.1 | Positive | No | MC | MC | |
| 5 | 10 y | F | FA | NA | No | 1.4 | Positive | No | CC | CC | |
| 6 | 4 y | M | Thal | NA | No | 6 | Positive | No | MC | MC | |
| 7 | 6 y | F | Thal | NA | No | 2.5 | Positive | No | MC | MC | |
| 8 | 13 y | F | Thal | NA | No | 4 | Positive | No | MC | MC | |
| 9 | 19 y | F | Thal | NA | No | 2.6 | Positive | No | MC | MC | |
| 10 | 10 y | M | DC | NA | No | 2.2 | Positive | No | MC | MC | |
| 11 | 4 y | F | ALL | NA | Yes | 3.2 | Negative | No | CC | CC | |
| CBT-ud | |||||||||||
| 12 | 5 y | M | ALL | 1 class II | Yes | 9.7 | Positive | Yes (II) | CC | CC | |
| 13 | 5 mo | F | Osteop | 0 | No | 13 | Negative | Yes (II) | CC | CC | |
| 14 | 5 y | M | ALL | 0 | Yes | 4 | Positive | Yes (I) | CC | CC | |
| 15 | 5 y | M | ALL | 1 class I | Yes | 4.7 | Negative | No | CC | CC | |
| 16 | 2 y | M | JMML | 1 class I | No | 5.2 | Positive | Yes (II) | CC | CC | |
Thal indicates thalassemia; NA, not applicable; CC, complete donor chimerism; NBL, neuroblastoma; MC, mixed donor/recipient chimerism; FA, Fanconi anemia; DC, dyskeratosis congenita; ALL, acute lymphoblastic leukemia; Osteop, osteopetrosis; and JMML, juvenile myelomonocytic leukemia.